

# Lymphoma Therapeutics: Market Research Report

<https://marketpublishers.com/r/L475D36FA49EN.html>

Date: April 2010

Pages: 752

Price: US\$ 3,950.00 (Single User License)

ID: L475D36FA49EN

## Abstracts

This report analyzes the worldwide markets for Lymphoma Therapeutics in US\$ Million.

The report provides separate comprehensive analytics for US, Europe, and Rest of World.

Annual estimates and forecasts are provided for each region for the period 2006 through 2015.

The report profiles 93 companies including many key and niche players such as Allos Therapeutics, Inc., Astellas Pharma US, Inc., Biogen Idec, Biolex Therapeutics, Inc., Biovest International, Inc., Cell Therapeutics, Inc, Cephalon, Inc., Chugai Pharmaceutical Co., Ltd., Cyclacel Pharmaceuticals, Inc., Eisai, Ltd., EpiCept Corp., F.Hoffmann-la Roche Ltd., Genentech, Inc., Genmab, Genitope Corp., Genzyme Corporation, GlaxoSmithKline, Plc, Hana Biosciences, Inc., ImmunoGen, Inc., InNexus Biotechnology, Inc., and Millennium Pharmaceuticals, Inc.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.

## Contents

### I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations

Disclaimers

Data Interpretation & Reporting Level

Quantitative Techniques & Analytics

Product Definitions and Scope of Study

Types of Lymphomas

Hodgkin's lymphoma

Non-Hodgkin's lymphoma

### II. EXECUTIVE SUMMARY

#### 1. GLOBAL OUTLOOK

Global Lymphoma Therapeutics Market to Surge

Europe Leads the Global Lymphoma Therapeutics Market

Lymphoma Incidence and Mortality Rates On the Rise

Incidence of Hodgkin's Lymphoma - High in West Asia

**Table 1.** Age-Standardized Incidence Rates for Hodgkin's Lymphoma in Select Countries Worldwide (2002) (includes corresponding Graph/Chart)

**Table 2.** Age-Standardized Mortality Rates for Hodgkin's Lymphoma in Select Countries Worldwide (2002) (includes corresponding Graph/Chart)

Rituxan's Dominance - A Major Hurdle to Other Emerging Drugs

Huge Unmet Needs to Drive Product Innovation

Radioimmunotherapy Drug Penetration Continues to Remain Lower

**Table 3.** Monthly Cost of Select Non-Hodgkin's Lymphoma Treatments (2009)

Sales of Zevalin to Gain Momentum

Combination Drugs – A Potential Winning Option for Manufacturers

Existing Drugs for Lymphoma

Select Approved Drugs In Lymphoma Treatment

Rituxan – the Undisputed Leader in NHL Drugs

Key Indications for Rituxan in the US

Zevalin (Biogen Idec)

Overview

Administration

Efficacy

Bexxar (GlaxoSmithKline)

Ribomustin®/Treanda®

Pipeline Drugs for Lymphoma

Select Pipeline Drugs In Lymphoma Treatment

Select Vaccines In Pipeline for Lymphoma Treatment

Pixantrone (Cell Therapeutics)

Affinitor (Novartis)

SGN-35 (Seattle Genetics)

SAR3419 (ImmunoGen, Inc.)

Overview of Treatment Options for NHL

Chemotherapy

Radiotherapy

Antibody Therapy

Stem Cell Transplants

## **2.PRODUCT OVERVIEW**

Lymphomas

Types of Lymphomas

Hodgkin's lymphoma

Non-Hodgkin's lymphoma

Classification – Based on Type of Cells Involved

Hodgkin's Lymphomas

Natural Killer (NK) and Mature T cell Neoplasms

Mature B cell Neoplasms

Classification - Based on Disease Progression

Indolent Lymphomas

Aggressive Lymphomas

Background

Signs and Symptoms

Etiology and Risk Factors

Immunological functions

Infections  
Lifestyle Factors  
Diagnosis of Lymphoma  
Prognosis  
Treatment of Lymphoma

### **3.DRUG APPROVALS**

Gloucester Obtains FDA Clearance for Istodax® in Treating CTCL  
Allos Obtains FDA Approval for FOLOTYN™  
Spectrum Receives FDA Approval for Zevalin® Expanded Label  
Genzyme Receives European Commission Approval for Mozobil®  
Cephalon Obtains FDA Approval for TREANDA for Treating Indolent NHL  
GSK Receives European Approval for Atriance®

### **4.RECENT INDUSTRY ACTIVITY**

Celgene to Acquire Gloucester Pharmaceuticals  
Scientists at Cornell Discover New Molecular Mechanism for Treating NHL  
CTI Seeks Orphan Drug Designation for Pixantrone in Europe  
FDA's ODAC Recommends Romidepsin's Approval  
Seattle Genetics Completes Enrollment for Brentuximab Vedotin  
InNexus Biotechnology to Initiate Business Development for DXL625  
Allos Therapeutics Introduces focusonptcl.com  
InNexus Inks Letter of Intent with Genhelix  
Pfizer Acquires Wyeth  
LLS and FORMA Join Hands to Accelerate Development of New Therapies  
Biovest and idis Ink Partnership Deal for Distribution of BiovaxID®  
SymBio Pharmaceuticals Signs a License Agreement with Eisai  
Seattle Genetics Receives Fast Track Designation from FDA for SGN-35  
Spectrum Acquires ZEVALIN® from RIT Oncology  
EpiCept Announces Crinobulin as Generic Name for EPC2407  
CTI Enters Into a Joint Venture with Spectrum Pharmaceuticals  
Allos Receives Orphan Drug Designation for Pralatrexate from FDA  
Takeda Acquires Millennium Pharmaceuticals

### **5.FOCUS ON SELECT GLOBAL PLAYERS**

Allos Therapeutics, Inc. (US)

Astellas Pharma US, Inc. (US)  
Biogen Idec (US)  
Biorex Therapeutics, Inc. (US)  
Biovest International, Inc. (US)  
Cell Therapeutics, Inc. (US)  
Cephalon, Inc. (US)  
Chugai Pharmaceutical Co., Ltd. (Japan)  
Cyclacel Pharmaceuticals, Inc. (US)  
Eisai, Ltd. (Japan)  
EpiCept Corp. (US)  
F. Hoffmann-la Roche Ltd. (Switzerland)  
Genentech, Inc. (US)  
Genmab (Denmark)  
Genitope Corp. (US)  
Genzyme Corporation (US)  
GlaxoSmithKline, Plc. (UK)  
Hana Biosciences, Inc. (US)  
ImmunoGen, Inc. (US)  
InNexus Biotechnology, Inc. (Canada)  
Millennium Pharmaceuticals, Inc. (US)

## **6.GLOBAL MARKET PERSPECTIVE**

**Table 4.** World Recent Past, Current & Future Analysis for Lymphoma Drugs Market by Geographic Region – US, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US\$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

**Table 5.** World 10-year Perspective for Lymphoma Drugs Market by Geographic Region – Percentage Breakdown of Value Sales for US, Europe and Rest of World Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart)

### **III. MARKET**

#### **1.UNITED STATES**

##### **A. MARKET ANALYSIS**

Rising Incidence of Lymphomas to Fuel Market Growth  
Mortality Rate Slips  
Lymphomas – The Third Leading Cause of Cancer in Children

**Table 6.** Percentage Breakdown of Cancer Incidence in US Children by Type (2006)  
(includes corresponding Graph/Chart)

White Children – Most Susceptible to Lymphomas

**Table 7.** Incidence of Lymphoma in US Children in 2006 (includes corresponding Graph/Chart)

Lymphoma Fact Sheet  
Incidence Rate Rises in Afro-Americans

**Table 8.** US Lymphoma Incidence Rates in Men of All Ages by Race: 2002-2006  
(includes corresponding Graph/Chart)

**Table 9.** US Lymphoma Incidence Rates in Women of All Ages by Race: 2002-2006  
(includes corresponding Graph/Chart)

**Table 10.** US Lymphoma Mortality Rates in Men of All Ages by Race: 2002-2006  
(includes corresponding Graph/Chart)

**Table 11.** US Lymphoma Mortality Rates in Women of All Ages by Race: 2002-2006  
(includes corresponding Graph/Chart)

Select Players in the Region  
New Drug Approvals  
Strategic Corporate Developments

## **B. MARKET ANALYTICS**

**Table 12.** US Recent Past, Current & Future Analysis for Lymphoma Drugs Market with Annual Sales in US\$ Million for Years 2006 through 2015 (includes corresponding

Graph/Chart)

## **2.EUROPE**

### **A. MARKET ANALYSIS**

Europe – The Largest Market for Lymphoma Therapeutics Worldwide  
Incidence of NHL Continues to Climb

**Table 13.** Annual Incidence of Non-Hodgkin’s Lymphomas in Europe: 2003-2010  
(includes corresponding Graph/Chart)

**Table 14.** Incidence Rates of Key Types of Non-Hodgkin’s Lymphomas in Europe:2006  
(includes corresponding Graph/Chart)

Immunotherapeutic Drugs Dominate the Market  
New Drugs to Transform Non-Hodgkin's Lymphoma Market  
Restraining Forces Loom Large Over New Drugs  
An Overview of Lymphomas in United Kingdom

**Table 15.** Hodgkin’s Lymphoma Incidence in UK (2006)

**Table 16.** Hodgkin’s Lymphoma Incidence in UK by Sex (2006): Percentage  
Breakdown by Age Group (includes corresponding Graph/Chart)

Select Players in the Region  
New Drug Approvals  
Strategic Corporate Developments

### **B. MARKET ANALYTICS**

**Table 17.** European Recent Past, Current & Future Analysis for Lymphoma Drugs  
Market with Annual Sales in US\$ Million for Years 2006 through 2015 (includes  
corresponding Graph/Chart)

## **3.REST OF WORLD**

## A. MARKET ANALYSIS

Rest of World Lymphoma Therapeutics Market to Witness Rapid Growth  
Select Players in the Region  
Strategic Corporate Developments

## B. MARKET ANALYTICS

**Table 18.** Rest of World Recent Past, Current & Future Analysis for Lymphoma Drugs Market with Annual Sales in US\$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

## IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 93 (including Divisions/Subsidiaries - 104)

Region/CountryPlayers

The United States

Canada

Japan

Europe

France

Germany

The United Kingdom

Spain

Rest of Europe

Asia-Pacific (Excluding Japan)



## I would like to order

Product name: Lymphoma Therapeutics: Market Research Report

Product link: <https://marketpublishers.com/r/L475D36FA49EN.html>

Price: US\$ 3,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/L475D36FA49EN.html>